(c) 2024 PillSync.com

lisinopril 30 mg

1 INDICATIONS AND USAGE Lisinopril tablets are an angiotensin converting enzyme (ACE) inhibitor indicated for: • Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) • Adjunct therapy for heart failure (1.2) • Treatment of Acute Myocardial Infarction (1.3) 1.1 hypertension Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets may be administered alone or with other antihypertensive agents [see Clinical Studies (14.1)]. 1.2 heart failure Lisinopril tablets are indicated to reduce signs and symptoms of heart failure in patients who are not responding adequately to diuretics and digitalis [see Clinical Studies (14.2)]. 1.3 Reduction of Mortality in Acute Myocardial Infarction Lisinopril tablets are indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of Acute Myocardial Infarction. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers [see Clinical Studies (14.3)].

legacy pharmaceutical packaging, llc


8 months ago ROUND RED E5 lisinopril 30 mg

ROUND RED E5

8 months ago ROUND RED E5 lisinopril 30 mg

E5 ROUND RED

16 HOW SUPPLIED/STORAGE AND HANDLING

LISINOPRIL Tablets USP 2.5 mg are white colored, round, flat faced beveled edge tablets, debossed with "E 1" on one side and plain on the other side. Unit of Use Bottles of 90: 2.5mg (NDC 68645-608-90)

LISINOPRIL Tablets USP 5 mg are pink colored, round, flat faced beveled edge tablets, debossed with "E 2" and separated by scored line on one side and plain on the other side. Unit of Use Bottles of 90: 5mg (NDC 68645-609-90)

LISINOPRIL Tablets USP 10 mg are pink colored, round, flat faced beveled edge tablets, debossed with "E 3" on one side and plain on the other side. Unit of Use Bottles of 90: 10mg (NDC 68645-610-90)

LISINOPRIL Tablets USP 20 mg are red colored, round, flat faced beveled edge tablets, debossed with "E 4" on one side and plain on the other side. Unit of Use Bottles of 90: 20mg (NDC 68645-611-90)

LISINOPRIL Tablets USP 30 mg are red colored, round, flat faced beveled edge tablets, debossed with "E 5" on one side and plain on the other side. Unit of Use Bottles of 90: 30mg (NDC 68645-612-90)

LISINOPRIL Tablets USP 40 mg are yellow colored, round, biconvex tablets, debossed with "E 6" on one side and plain on the other side. Unit of Use Bottles of 90: 40mg (NDC 68645-613-90) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.


More pills like ROUND E5

Related Pills

lisinopril 40 mg

legacy pharmaceutical packaging, llc

lisinopril 2.5 mg

legacy pharmaceutical packaging, llc

lisinopril 5 mg

legacy pharmaceutical packaging, llc

lisinopril 10 mg

legacy pharmaceutical packaging, llc

lisinopril 20 mg

legacy pharmaceutical packaging, llc

lisinopril 30 mg

legacy pharmaceutical packaging, llc

lisinopril 40 mg

legacy pharmaceutical packaging, llc

dexamethasone 2 mg

amneal pharmaceuticals ny llc

dexamethasone 2 mg

amneal pharmaceuticals ny llc

drospirenone and ethinyl estradiol kit

glenmark pharmaceuticals inc., usa

gabapentin capsule

epic pharma, llc

quetiapine 25 mg

aurobindo pharma limited












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site